Clinical Trials › NCT05961644
RecruitingPhase 2
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
Sponsored by Institute of Psychiatry and Neurology, Warsaw
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 188
Target enrollment
Oct 2022
Start date
Oct 2027
Expected completion
Interventions / Treatments
Cladribine Subcutaneous Injection0.9% Chloride Injection Sodium
Conditions studied
Multiple Sclerosis, Secondary ProgressiveMultiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 2 trials
Browse all Phase 2 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.